Center for Gene and Cell Therapy Co-founded by Miltenyi and ATLATL in Shanghai

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190320005577/en/

(Photo: Business Wire)

ATLATL has the world’s largest shared Class-A level laboratory space, designed as a launchpad for high-potential life sciences. It offers fully permitted laboratories and office space for scientists and entrepreneurs. To meet the demands of growing research teams, ATLATL provides full service state-of-the-art facilities, the most advanced instruments, professional operations support, skilled laboratory personnel, on-site CROs, and the most creative Module research services, serving teams of various size who need to begin immediate laboratory operations. The Center is approximately 25,000 square feet, functions as a talent training center, expedites process development, and cell and gene therapy platforms. The center includes specialized laboratories for cell collection, separation, production, microscopic imaging, and storage and transportation.

In recent years, advances in gene editing technology and viral vectors, gene and cell therapy has developed from theory to reality with major breakthroughs, as a promising emerging sector in medicine. Companies engaged in this field are sought in capital markets, and a large number of companies have completed IPO listings, including Bluebird Bio, Celladon, Orchard, and Spark. Many gene and cell therapies have demonstrated impressive results in clinical trials and more treatments could be approved in coming years.

ATLATL and Miltenyi spent nearly one year on planning and construction, finally built the ATLATL-MACS Center in March 2019 with a specialized focus to remove hurdles encountered in current treatments. The Center offers a complete research and development platform and will actively train researchers, work with more R&D teams to conduct new process development and application discovery, establish complete standardized operating procedures, assist pharmaceutical companies conduct accurate disease diagnosis and efficacy evaluations, accelerating clinical transformation and commercialization of gene and cell therapy.

The ATLATL-MACS Center covers the biomedical industry chain and will gather a series of innovative teams, which have important strategic significance for the development of local life sciences. The center will provide services to biological companies through more than 10 million euro cutting-edge instruments and expert team. Miltenyi’s CliniMACSProdigy is the unique automated CAR-T preparation instrument, greatly speeding up the cell therapy and development in clinical applications. The Center will lower the gene and cell therapy industry innovation threshold locally and globally.

Miltenyi Biotec has previously collaborated with many giant pharmaceuticals, such as GlaxoSmithKline (GSK) on the “industrialization” of cell and gene therapy. Differently, the cooperation between Miltenyi and ATLATL is an open platform to biotech companies. The center will help biopharmaceutical companies and scientific research institutions integrate R&D, training, commercialization. It will greatly reduce the initial cost in research and development and help companies accelerate the clinical transformation and commercialization of cell and gene therapy to benefit more patients.

{ATLATL Center is a component of ATLATL Innovation Cluster (AIC), which is an ecosystem with educational and research centers, on-site CROs, entrepreneurship, venture capital, and life sciences companies. AIC strives to increase research density and accelerate research commercialization. Innovative teams can jumpstart with turnkey solutions, leverage resources more efficiently, and reach milestones faster than ever.}

View source version on businesswire.com: https://www.businesswire.com/news/home/20190320005577/en/